USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Intel Boosts Malaysia Operations with Additional RM860 Million Investment 
Taiwan Opposition Criticizes Plan to Block Chinese App Rednote Over Security Concerns 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
